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 Abstract 
  Objectives:   To determine if mild cognitive impairment (MCI) represents a continuum of cogni-
tive and functional deficits.   Methods:   Clinical data of 164 subjects with no dementia (ND, n = 
52), uncertain dementia (n = 69), and mild probable Alzheimer’s disease (AD, n = 43) were 
  reviewed. Uncertain dementia patients were classified as pre-MCI (n = 11), early amnestic MCI 
(e-aMCI, n = 15) and late amnestic MCI (l-aMCI, n = 15). Cognitive assessments [Chinese Mini-
Mental State Examination (CMMSE) and a validated neuropsychological battery], functional as-
sessments (Lawton’s scale for instrumental activities of daily living) and neuroimaging (isch-
emic lesions and medial temporal lobe atrophy) were reviewed.  Results:  ND, aMCI and mild AD 
subjects demonstrated a significant trend for worsening performance for all cognitive and 
functional measures (ANOVA, p   !   0.05). Pre-MCI subjects performed significantly better than 
aMCI subjects in all verbal memory domains (p  !  0.001), while l-aMCI had worse functional per-
formance (p = 0.007), a trend towards greater depressive symptoms (p = 0.05) and higher me-
dial temporal lobe atrophy scores (p = 0.06). l-aMCI subjects were more likely than either pre-
MCI or e-aMCI to progress to dementia over a mean follow-up period of 2.5 years (46.7 vs. 9.1 
and 20.0%, respectively).  Conclusions:   Clinical delineation of aMCI allows the differentiation of 
those likely to progress for better correlation to biomarker development. 
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 Introduction 
  The pre-dementia at-risk state of mild cognitive impairment (MCI) is a heterogeneous 
entity which requires better characterization. This important transitional continuum differs 
from the normal cognitive state by the presence of objective cognitive impairment, but there 
is insufficient decline in functional status to fulfill the diagnosis of dementia   [1]  . Previously, 
subtypes of MCI based on the pattern of neuropsychological impairment have been pro-
posed, where such distinction may mark incipient forms of different dementias  [2] . With the 
advent of disease-modifying treatments for Alzheimer’s disease (AD), the amnestic subtype 
of MCI (aMCI) in particular has received much attention as a possible precursor to this com-
monest of dementia states   [3]  . While such a classification may aid in etiological evaluation, 
it still cannot address the heterogeneity of cognitive decline observed in the spectrum of MCI 
subjects, or its associated impact on the latency of conversion to dementia, which was al-
luded to in an earlier report   [4]  .
    Additionally, the study of MCI has yielded various challenging questions. Standardized 
screening instruments and neuropsychological scales for definitive diagnosis of the general 
MCI cohort are not agreed upon   [5]  . Difficulties remain in defining the boundaries between 
normal aging and MCI, or MCI and mild dementia, as the distinction depends on the degree 
of functional impairment and its mode of measurement  [6] . Studies examining the conversion 
of MCI to dementia have not accurately identified a subset which has a higher predilection for 
AD pathology, although multi-domain aMCI have been suggested  [7] . Finally, therapeutic tri-
als with cholinesterase inhibitors conducted on criterion-defined MCI subjects have also not 
shown any clear benefits in delaying cognitive deterioration or the onset of dementia   [8–10]  .
  Despite the heterogeneity observed, the pathological validity of aMCI has been support-
ed by conversion rates to dementia of   1  60% at a 2-year follow-up   [11]  . More accurate char-
acterization of aMCI subjects will allow research to focus on those subjects who are most at 
risk of conversion to AD   [12]   and who would best stand to gain from early therapeutic inter-
ventions. It is important to realize that there is a window of opportunity for identifying sub-
jects at a phase when pathology has already begun, but clinical diagnosis of AD is not yet 
achievable.
    In our current study, we retrospectively examined the clinical data of subjects attending 
a memory clinic with the following aims: (i) to characterize patients with subjective cogni-
tive complaints in order to discern distinctive clinical subgroups within the entity of MCI 
using the global staging instrument of the Clinical Dementia Rating (CDR) scale   [13]  ; (ii) to 
evaluate the performances of clinically defined aMCI subjects upon cognitive screening test-
ing, and neuropsychological and functional assessments, and (iii) to determine whether such 
a clinical classification system is supported by initial data on dementia conversion. We hy-
pothesized that aMCI is a heterogeneous construct encompassing subjects with variable de-
grees of impairment, and there exists a spectrum of cognitive and functional deficits span-
ning from normal cognition to early dementia.
  Patients  and  Methods 
  Setting and Participants 
  We reviewed all clinical information routinely captured within the memory clinic data-
base for subjects with memory complaints but no dementia (ND), aMCI, and mild AD pre-
senting for the first time to the Cognition and Memory Disorder Service of the Tan Tock 
Seng Hospital in Singapore, from the period of January 2007 to December 2008. Data were 
eligible for inclusion if the subject was 55 years or older; had a diagnosis of ND, pre-MCI, 115
Dement Geriatr Cogn Disord Extra 2011;1:113–123
 DOI:  10.1159/000327519 
EXTRA
  Chan et al.: Disease Spectrum of Amnestic MCI 
www.karger.com/dee
  © 2011 S. Karger AG, Basel 
  Published online: April 27, 2011 
aMCI (see below), or mild probable AD and completed standardized clinical and neuropsy-
chological evaluation. We excluded subjects with early dementia due to other etiologies and 
subjects with moderate- or advanced-stage dementia as indicated by a global CDR rating  6 2. 
Subsequent information regarding conversion to dementia was reviewed at an arbitrary cut-
off date set at the end of June 2010 (this gives an approximate follow-up of 2.5 years for the 
majority of subjects). Conduct of the study was approved by the institutional review board.
  C l i n i c a l   A s s e s s m e n t  
  All patients underwent detailed clinical evaluation including comprehensive cognitive 
history taking from the patient and a reliable collateral source, and physical examination. 
Relevant laboratory investigations and neuroimaging were also performed to exclude poten-
tially reversible causes of cognitive impairment   [14]  . Patients were administered the Chinese 
Mini-Mental Status Examination (CMMSE) for mental state screening. The CMMSE had 
been locally validated, and modifications made to suit the cultural context of Singapore had 
been described previously. This includes omitting the question on season; the two questions 
on patient’s town and county were combined into a single question yielding a total score of 
28 instead of 30, and a cutoff score adjusted for severity of 20 for dementia  [15] . We employed 
the Cornell Scale for Depression in Dementia (CSDD) for mood evaluation as a prior local 
comparative study indicated better diagnostic properties for this instrument compared to 
the Geriatric Depression Scale. While scores ranged from 0 to 38, a value   6  6 would suggest 
possible depression in the local setting   [16, 17]  . The functional staging tool of CDR, again 
validated locally, was scored by a clinician after initial assessment   [18]  .
    Information obtained from a reliable informant was used to complete the Lawton and 
Brody’s scales for instrumental activities of daily living (iADL)   [19]  . The scale comprises as-
sessment of eight common daily activities: using telephone, shopping, meal preparation, house-
keeping, laundry, use of transportation, self-administration of drugs, and handling of financ-
es. The total score spans the range from 0 (total dependence) to 23 (total independence)   [20]  .
  Neuropsychological  Battery 
  Our neuropsychological assessment battery was modeled according to the Consortium 
to Establish a Registry for Alzheimer’s Disease psychometric instruments and had been lo-
cally validated with education adjustment   [21]  . The battery consists of the following items:
    (1)  Word list memory task: immediate recall, delayed recall and recognition memory, all of 
which ascertain different aspects of verbal memory. 
  (2)  Verbal fluency (animal naming), which appraises semantic language and executive 
functioning. 
  (3)  Modified Boston Naming Test, which assesses language skills. 
  (4)  Block design, object assembly subtest of the Wechsler Adult Intelligence Scale-Revised 
and constructional praxis, all of which evaluate visuospatial abilities. 
 Neuroimaging 
 All neuroimaging studies (computed tomography or magnetic resonance imaging) were 
performed in the same center; they were reviewed for the presence of medial temporal lobe 
atrophy (MTA), white matter lesions and infarcts by a single rater blinded to the clinical sta-
tus of the patient. Coronal slices of MRI studies parallel to the brainstem axis and perpen-
dicular to the hippocampal axis were reviewed and an MTA score of 0 (no atrophy) to 4 
  (severe atrophy) was assigned based on the visual estimation of the volume of the medial 
temporal lobe   [22]  . The greater of either hemispheric score was then taken as the overall 
MTA score. An age-related scale rating white matter changes   [23]   was used for the grading 
of white matter lesions. Five different regions (frontal, parieto-occipital, temporal, infraten-116
Dement Geriatr Cogn Disord Extra 2011;1:113–123
 DOI:  10.1159/000327519 
EXTRA
  Chan et al.: Disease Spectrum of Amnestic MCI 
www.karger.com/dee
    © 2011 S. Karger AG, Basel
  Published online: April 27, 2011 
torial, and basal ganglia) were rated in the right and left hemispheres on a 4-point scale. The 
global white matter score was then derived from the summation of the individual scores 
(range 0–30). Information on the presence or absence of infarcts (as a categorical variable) 
was obtained from the report of a neuroradiologist who reviewed the scan.
  Subject  Classification 
 The clinical diagnosis is assigned via a multi-disciplinary approach with physician, cog-
nition nurse clinician and psychologist inputs. Subjects classified as ND were those individ-
uals who presented to the Memory Clinic with cognitive complaints, but who after clinical 
evaluation, including neuropsychological assessment, were found to lack subjective and ob-
jective evidence for dementia, or did not satisfy the criteria for inclusion (i.e. subjective mem-
ory complaints only but no MCI). Conversely, patients diagnosed with mild AD were those 
who met criteria for probable AD as defined by the National Institute of Neurological and 
Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Associa-
tion   [24]  . Additionally, they would have a global CDR score of either 0.5 or 1, indicating the 
mild nature of their dementia.
  Subjects with a possible diagnosis of MCI were further discussed in a separate consensus 
meeting involving geriatricians running the Memory Clinic, with nurse clinician, psycholo-
gist and neurologist input to verify the diagnosis and to further determine its subtype ac-
cording to the revised criteria proposed by Petersen et al.   [25]  . Thus, MCI subjects are op-
erationally defined as individuals with (1) subjective memory complaints, (2) presence of 
objective cognitive impairment (neuropsychological domain testing noted to be   1  1.0 SD be-
low education-adjusted means obtained from earlier normative studies)   [21]  , (3) preserved 
overall general function, and (4) absence of clinical dementia as defined by global CDR   ! 1 
and failure to meet DSM-IV criteria for dementia (Diagnostic and Statistical Manual, edition 
4). We then selected the group of subjects classified as aMCI based on their impaired perfor-
mance in the delayed word list recall task for analysis. We used the arbitrary cutoff of   1 1.0 
SD as determinant of impairment in psychometric domains as this was noted to have great-
er predictive power for the development of dementia in a previous population study   [26]  .
    To further explore the spectrum of pathology in aMCI, our study cohort comprised 
early (e-aMCI) and late aMCI (l-aMCI) according to their scores obtained for the CDR sum 
of boxes (CDR-SB;   fig. 1  ). Those with CDR-SB   ^  1.5 are classified as e-aMCI, while the rest 
are assigned to the l-aMCI category. We believe that such a classification based on a global 
assessment scale such as the CDR-SB can delineate unique subtypes for valid comparison of 
baseline features. In addition, we also included a small group of patients with significant 
subjective as well as clinician’s impression of memory complaints but who did not display 
impairment on standard neuropsychological testing to satisfy the inclusion criteria of MCI 
(i.e. global CDR = 0.5, but no domains   1  1.0 SD below adjusted norms obtained from a prior 
validation study). They were classified as pre-MCI for the purpose of this study. We further 
reviewed the data on progression for these subjects with regard to their cognitive status (un-
changed, deteriorated or conversion to dementia).
  Statistical  Analysis 
  Analysis was performed with SPSS for Windows (version 16.0; SPSS, Inc., Chicago, Ill., 
USA). In comparing psychological performances, z-scores were computed for all the neuro-
psychological test results based on education-adjusted norms obtained from a prior valida-
tion study in the local population   [21]  . One-factor ANOVAs with post hoc Bonferroni com-
parisons were performed to analyze the mean differences between groups for continuous 
variables, while comparisons for proportions were performed using the     2   test. The level of 
statistical significance was set at 0.05.117
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  R e s u l t s  
 Baseline  Demographics 
  Of the 581 records available during the defined study period, 164 subjects with ND (n = 
52), questionable dementia status (n = 69) and mild probable AD (n = 43) were considered 
for study inclusion. We subsequently excluded 28 subjects classified as non-aMCI (  fig. 1  ), 
leaving a final analytical sample of 136 subjects. Of these, 11 subjects were deemed to have 
pre-MCI. The remaining 125 subjects with ND, aMCI and mild AD comprise predominant-
ly Chinese subjects (n = 113, 90.4%), with a preponderance of females (n = 76, 60.8%). The 
mean age of the subjects was 71.6   8   9.4 years, with ND subjects being significantly younger 
than aMCI and those with early AD (mean age of ND = 64.7   8   9.2 years, vs. 74.5   8   6.2 and 
76.6   8   6.7 years in aMCI and mild AD groups, respectively; ANOVA, p   !   0.001). However, 
there was no significant difference in terms of their years of education or duration of symp-
toms (  table 1  ). The mean follow-up period for the entire group was 2.5   8   0.6 years.
    Neuropsychological and Functional Profiles 
 CMMSE scores were noted to decline progressively from the categories of ND, aMCI and 
mild AD (mean scores = 25.50  8  2.89, 21.97  8  4.03 and 20.21  8  3.96, respectively; ANOVA, 
p   !   0.001). Not unexpectedly, the three clinical groups also demonstrated a spectrum of 
worsening neuropsychological test performances, achieving statistical significance across all 
cognitive domains upon ANOVA testing (  table 2  ). There were significant differences upon 
comparison between ND versus aMCI in terms of immediate memory, recognition memory, 
delayed memory (post hoc Bonferroni testing, all p   !   0.001), category fluency (p = 0.039), 
block design and object assembly (both p = 0.008). aMCI subjects also performed signifi-
cantly better compared to those with mild AD in tests of delayed memory (p = 0.002), cate-
gory fluency (p = 0.02), and in the Boston Naming Test (p = 0.001), further demonstrating 
the validity of such a clinical classification. The groups, however, did not demonstrate sig-
nificant differences in the presence of depression as recorded by the CSDD (mean scores for 
ND, aMCI and mild AD = 5.47   8   4.96, 4.76   8   4.76 and 4.26   8   3.86, respectively; p = 0.46). 
  Fig. 1.   MCI subject classification. 118
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The presence of increasing functional disability was also highlighted by the significant de-
terioration in the total Lawton score across the clinical spectrum (mean scores for ND, aMCI 
and mild AD = 21.98   8   2.65, 19.00   8   4.20 and 15.24   8   4.14, respectively; ANOVA, p   !  
0.001).
  aMCI  Subtype  Comparisons 
  aMCI subjects were further classified as e-aMCI (n = 15) and l-aMCI (n = 15) based on 
their CDR-SB scores and compared with pre-MCI subjects (n = 11). There were no significant 
differences between the three categories of patients in terms of gender, race, age, education-
al attainment or duration of symptoms. There was a trend for poorer scores in CMMSE span-
ning the three MCI categories (pre-MCI, e-aMCI and l-aMCI mean scores = 26.09   8   1.38, 
23.33   8   3.56 and 20.60   8   4.12, respectively; ANOVA, p = 0.001;   table 3  ). With regard to 
neuropsychological performance, there were significant trends for worsening performance 
Table 1.   Baseline characteristics of the subjects with ND, aMCI (e-aMCI and l-aMCI) and mild AD
ND
(n = 52)
aMCI
(n = 30)
Mild AD
(n = 43)
p value
(ANOVA/2)
Females, n (%) 30 (57.7) 17 (56.7) 29 (67.4) 0.54
Chinese race, n (%) 49 (94.2) 29 (96.7) 35 (81.4) 0.23
Age (mean 8 SD), years 64.789.2 74.586.2 76.686.7 <0.001
Years of education (mean 8 SD) 8.1 (4.9) 6.9 (5.1) 6.8 (4.9) 0.39
Duration of symptoms (mean 8 SD), years 2.382.0 1.981.8 2.181.3 0.57
Mean follow-up period (mean 8 SD), years 2.480.5 2.880.8 2.480.6 0.06
MTA score (mean 8 SD) 0.780.9 1.981.1 1.980.8 <0.004
Presence of lacunar infarcts, n (%) 12 (24.5) 13 (44.8) 3 (7.5) 0.02
WML global score (mean 8 SD) 4.882.5 5.083.0 4.183.2 0.38
Table 2.  Clinical and neuropsychological evaluation of subjects with ND, aMCI (e-aMCI and l-aMCI) and 
mild AD
ND
(n = 52)
aMCI
(n = 30)
Mild AD
(n = 43)
p value 
A NOVA
2 test
ND vs. 
aMCI
AD vs. 
aMCI
Cognitive and functional testing
CMMSE (mean 8 SD), n/28 25.5082.89 21.9784.03 20.2183.96 <0.001 <0.001 0.12
CSDD (mean 8 SD) 5.4784.96 4.7684.76 4.2683.81 0.46 1.00 1.00
Total Lawton score 
(mean 8 SD), n/23 21.9882.65 19.0084.20 15.2484.14 <0.001 0.002 <0.001
Neuropsychological testing (z-scores)
Immediate memory  0.17 (1.08) –1.10 (1.07) –1.67 (1.11) <0.001 <0.001 0.09
Recognition memory 0.15 (1.15) –1.33 (1.37) –1.86 (2.13) <0.001 <0.001 0.50
Delayed memory 0.24 (0.99) –1.39 (0.50) –2.07 (0.72) <0.001 <0.001 0.002
Animal category –0.61 (1.20) –0.70 (1.02) –1.44 (1.02) <0.001 0.04 0.02
Boston Naming Test –0.31 (1.36) –0.65 (1.37) –2.13 (2.06) <0.001 1.00 0.001
Block design 0.89 (1.22) –0.63 (0.93) –1.01 (0.76) <0.001 0.008 0.37
Object assembly –0.11 (1.13) –0.88 (1.19) –0.97 (0.95) 0.001 0.008 1.00119
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in all three memory domains (ANOVA, p   !   0.001), with superior performance noted in the 
pre-MCI group. Amongst the non-memory domains, a trend for worsening performance was 
noted in the category fluency, although this did not reach statistical significance (ANOVA, 
p = 0.21). While not statistically significant, l-aMCI subjects were noted to have higher de-
pression scores than their pre-MCI and e-aMCI counterparts (mean score ANOVA, p = 0.05). 
Furthermore, l-aMCI subjects had significantly poorer performance in iADL as measured 
by the Lawton’s scale (mean score 16.93   8   4.97, vs. 20.50   8   2.07 and 20.93   8   2.02 in pre-
MCI and e-aMCI, respectively, ANOVA, p = 0.007).
  N e u r o i m a g i n g   F i n d i n g s  
 ND (24.5%) and aMCI (44.8%) subjects were more likely than AD (7.5%) to have lacunar 
infarcts upon neuroimaging (ANOVA, p = 0.02). However, there was no difference between 
groups in terms of the global scores for the presence of intracranial white matter leukoara-
iosis (WML; ANOVA, p = 0.38). Further analyses of subjects with pre-MCI, e-aMCI and
l-aMCI did not reveal any significant difference both in terms of presence of lacunar infarcts 
or intracranial WML (p = 0.36 and p = 0.06, respectively).
    The number of neuroimaging studies for MTA analyses was limited, with only 41 out 
of a possible 136 subjects having suitable imaging (coronal sections of the hippocampus 
were only available on selected MRI studies). Mean MTA scores were significantly lower for 
ND subjects than those with aMCI and AD (0.7   8   0.9, 1.9   8   1.1 and 1.9   8   0.8, respective-
ly; p = 0.04). A similar trend of increasing MTA score (greater atrophy) was noted for sub-
jects with pre-aMCI, e-aMCI and l-aMCI (0.7   8   1.0, 1.0   8   0.0 and 2.1   8   1.2, respectively; 
p = 0.06).
  Limited Conversion Data 
  Over the follow-up period, 11 of the 41 MCI subjects were diagnosed with dementia. The 
majority of patients received a diagnosis of AD (n = 7, 63.6%), with vascular dementia being 
Table 3.  Clinical, functional and neuropsychological test performance of subjects with pre-MCI and aMCI
Pre-MCI
(n = 11)
e-aMCI
(n = 15)
l-aMCI
(n = 15)
p   value
AN OVA pre-  vs. 
e-aMCI
e- vs. 
l-aMCI
Cognitive and functional testing
CMMSE (mean 8 SD), n/28 26.0981.38 23.3383.56 20.6084.12 0.001 0.140 0.10
CSDD (mean 8 SD) 2.5683.91 3.0784.03 6.5784.96 0.05 1.00 0.11
Total Lawton score 
(mean 8 SD), n/23 20.5082.07 20.9382.02 16.9384.97 0.007 1.00 0.009
MTA score (mean 8 SD) 0.6781.03 1.0080.00 2.1181.17 0.06 1.00 0.62
Presence of lacunar infarcts, n (%) 7 (63.6) 8 (53.3) 5 (35.7) 0.36
WML global score (mean 8 SD) 6.5583.08 3.9382.58 6.0781.15 0.057 0.09 0.17
Neuropsychological testing (z-scores)
Immediate memory 0.59 (0.74) –1.26 (0.98) –0.94 (1.16) <0.001      <0.001 1.00
Recognition memory 0.68 (0.40) –1.27 (1.47) –1.39 (1.32) <0.001      <0.001 1.00
Delayed memory 0.60 (0.59) –1.29 (0.32) –1.49 (0.63) <0.001      <0.001 0.90
Animal category –0.16 (0.73) –0.55 (1.09) –0.85 (0.98) 0.21 0.93 1.00
Boston Naming Test 0.42 (0.55) –0.67 (1.37) –0.64 (1.42) 0.06 0.10 1.00
Block design 0.20 (1.02) –0.70 (1.20) –0.56 (0.59) 0.06 0.08 1.00
Object assembly –0.15 (1.17) –0.99 (1.26) –0.78 (1.16) 0.22 0.27 1.00120
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the next most common diagnosis (n = 4, 36.3%). A significant trend for greater likelihood of 
conversion for subjects classified as pre-MCI (n = 1, 9.1%), e-aMCI (n = 3, 20.0%) and l-aMCI 
(n = 7, 46.7%;     2   test, p   !   0.001) was observed (  table 4  ).
  Discussion 
  Our study was able to demonstrate the isolation of an aMCI clinical entity with neuro-
psychological and functional properties which are distinct and intermediary for subjects 
with ND and mild AD. In addition, we noted that further stratification of aMCI subjects 
produces a clinical subset (l-aMCI) with worse performance in most testing domains, pos-
sibly with a higher degree of MTA, being at the greatest risk of conversion to dementia in the 
near term. Recent studies have reported the validation of accurate radiological and cerebro-
spinal fluid biomarkers for AD in its incipient stages  [27, 28] . It is thus more crucial than ever 
to emphasize the accurate clinical characterization of subjects with mild amnestic com-
plaints and correlate biological markers of disease activity with working phenotypes to en-
sure clinical relevance of research.
    In our current study, pre-MCI subjects had greater functional impairment than those 
with ND (mean iADL score 20.50   8   2.07 vs. 21.98   8   2.65) despite not fulfilling neuropsy-
chological criteria for MCI. Few studies have examined the utility of a clinical versus a neu-
ropsychological classification of MCI subjects. Storandt et al.   [29]   noted that subjects with a 
Clinical Dementia Rating scale global score of 0.5 who do not fulfill formal neuropsycho-
logical criteria for MCI (pre-MCI) may progress to dementia, indicating that AD may be 
identified at an even earlier stage than MCI. Yet another study found that subjects with ques-
tionable AD (CDR = 0.5) were more likely to convert to dementia if their CDR-SB score was 
  1  1.5   [30]  . In contrast, a recent large population study on MCI noted that classification of 
subjects with CDR 0.5 may be influenced by demographic, cognitive and clinical factors, 
with lower rates of conversion to dementia than those fulfilling neuropsychological criteria 
for MCI   [31]  . The utility of clinical stratification of subjects with subtle memory complaints 
therefore requires further clarification in subsequent prospective studies.
    The current study also highlighted the spectrum of functional abilities amongst this 
group of subjects with mild cognitive deficits, ranging from minimal deficits in the ND 
group to significant impairment in l-aMCI and mild AD subjects. Additionally, our study 
noted that functional impairment bears little correlation with the burden of intracranial 
ischemic lesions (both lacunar infarcts and WML), which were similar between the catego-
ries of MCI patients. Previous reports have alluded to the importance of functional assess-
ment in the evaluation of subjects with MCI who had been shown to perform poorer than 
age- and sex-matched cognitively unimpaired controls in iADL   [32]  . Mariani et al.   [33]   also 
noted that both memory deficits and executive dysfunction may account for the restriction 
in iADL   [33]  . As functional independence is the key to patient autonomy and quality of life, 
Table 4.   Conversion to dementia amongst MCI subtypes
Pre-MCI (n = 11) e-aMCI (n = 15) l-aMCI (n = 15)
Conversion to dementia, n (%) 1 (9.1)* 3 (20.0)* 7 (46.7)*
*   p < 0.001.121
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Wadley et al.   [34]   have suggested that the preservation of function be used as a meaningful 
outcome measure for interventional efforts in MCI subjects. However, more work in larger 
patient groups is still required to better characterize the relationship between the degree of 
functional impairment and the severity of cognitive decline for this at-risk group, where bur-
den of disease is usually mild.
    While we did not detect any difference in depressive symptoms between subjects with 
ND, aMCI and mild AD, it is interesting to note the disparity in CSDD scores of subjects 
with l-aMCI (with mean scores  1 6, suggesting the possibility of a depressive state) compared 
to the other MCI subtypes. In a recent study, Lu et al.   [35]   have reported that the presence of 
depression is predictive of progression of aMCI to AD, and donepezil treatment may modu-
late this increased risk. Edwards et al.  [36]  similarly noted the association of depressive symp-
toms with aMCI and an increased risk of progression to dementia in subjects with greater 
neuropsychiatric symptoms. It is highly likely that the affective symptoms demonstrated in 
these vulnerable MCI subjects reflect the underlying neurodegenerative process   [37]  , and 
their presence should warrant closer inspection and follow-up.
    Strengths of the current study include the comprehensive assessment of subjects with 
locally validated cognitive instruments, and the use of consensus-derived clinical classifica-
tion for aMCI and AD subjects. An important limitation of the study was that most of the 
ND subjects in our cohort have subjective memory complaints and may not be representative 
of normal elderly subjects in the general population, even though such an approach may be 
useful for clinicians in the memory clinic setting. Previous works have highlighted that the 
presence of subjective memory complaints is itself a risk factor for subsequent development 
of dementia   [38]  , and the ability to clinically differentiate this at-risk group from aMCI sub-
jects provides further credence to the concept of a spectrum of deficits in subjects with sub-
tle memory complaints which warrants further exploration. Finally, the psychometric bat-
tery employed did not have a specific executive function domain which might correlate with 
function on iADL assessment, although this is partially addressed by the inclusion of the 
category verbal fluency (animal naming) in the test, which requires a significant degree of 
executive functioning.
  In conclusion, findings of the current study suggest that further subtyping of aMCI sub-
jects was possible based on neuropsychological and functional performance, which could be 
represented by their CDR-SB scores. Accurate clinical characterization of aMCI is crucial for 
advancing our knowledge on disease progression and the development of suitable biomark-
ers for Alzheimer’s pathology. The utility of such a clinical classification system for sample 
enrichment in MCI therapeutic trials may be explored in future studies.
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